A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy

Ari Shinojima, Miki Sawa, Tetsuju Sekiryu, Yuji Oshima, Ryusaburo Mori, Chikako Hara, Yukinori Sugano, Aki Kato, Hitomi Asato, Mitsuko Yuzawa, Fumi Gomi, Yuichiro Ogura, Tatsuro Ishibashi, Tomoaki Nanri, Tsutomu Yasukawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To investigate functional and morphological changes in patients with chronic central serous chorioretinopathy after supplementation with antioxidants containing lutein or a placebo. Procedures: One hundred eyes of 100 patients were randomly divided into 2 groups, one taking tablets with lutein plus other antioxidants and the other taking a placebo for 6 months. Best-corrected visual acuity (BCVA) and the subfoveal fluid height on optical coherence tomography were measured. Results: Seventy-nine patients (37 in the supplementation and 42 in the placebo group) completed the 6-month follow-up. In the supplementation group, mean BCVA showed significant improvement (p = 0.003), while there was no significant change in the placebo group (p = 0.589). The mean subfoveal fluid height was significantly reduced, by 28.6%, in the supplementation group (p = 0.028), in contrast to 3.3% in the placebo group (p = 0.898). Conclusions: Antioxidant supplementation significantly reduced subfoveal fluid height. The impacts of antioxidant supplementation on BCVA remain to be elucidated in future studies.

Original languageEnglish
Pages (from-to)159-166
Number of pages8
JournalOphthalmologica
Volume237
Issue number3
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Central Serous Chorioretinopathy
Lutein
Antioxidants
Placebos
Visual Acuity
Optical Coherence Tomography
Tablets

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems

Cite this

A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. / Shinojima, Ari; Sawa, Miki; Sekiryu, Tetsuju; Oshima, Yuji; Mori, Ryusaburo; Hara, Chikako; Sugano, Yukinori; Kato, Aki; Asato, Hitomi; Yuzawa, Mitsuko; Gomi, Fumi; Ogura, Yuichiro; Ishibashi, Tatsuro; Nanri, Tomoaki; Yasukawa, Tsutomu.

In: Ophthalmologica, Vol. 237, No. 3, 01.04.2017, p. 159-166.

Research output: Contribution to journalArticle

Shinojima, A, Sawa, M, Sekiryu, T, Oshima, Y, Mori, R, Hara, C, Sugano, Y, Kato, A, Asato, H, Yuzawa, M, Gomi, F, Ogura, Y, Ishibashi, T, Nanri, T & Yasukawa, T 2017, 'A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy', Ophthalmologica, vol. 237, no. 3, pp. 159-166. https://doi.org/10.1159/000455807
Shinojima, Ari ; Sawa, Miki ; Sekiryu, Tetsuju ; Oshima, Yuji ; Mori, Ryusaburo ; Hara, Chikako ; Sugano, Yukinori ; Kato, Aki ; Asato, Hitomi ; Yuzawa, Mitsuko ; Gomi, Fumi ; Ogura, Yuichiro ; Ishibashi, Tatsuro ; Nanri, Tomoaki ; Yasukawa, Tsutomu. / A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. In: Ophthalmologica. 2017 ; Vol. 237, No. 3. pp. 159-166.
@article{2270949bd38d4b28ac6dcd17abac07dc,
title = "A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy",
abstract = "Purpose: To investigate functional and morphological changes in patients with chronic central serous chorioretinopathy after supplementation with antioxidants containing lutein or a placebo. Procedures: One hundred eyes of 100 patients were randomly divided into 2 groups, one taking tablets with lutein plus other antioxidants and the other taking a placebo for 6 months. Best-corrected visual acuity (BCVA) and the subfoveal fluid height on optical coherence tomography were measured. Results: Seventy-nine patients (37 in the supplementation and 42 in the placebo group) completed the 6-month follow-up. In the supplementation group, mean BCVA showed significant improvement (p = 0.003), while there was no significant change in the placebo group (p = 0.589). The mean subfoveal fluid height was significantly reduced, by 28.6{\%}, in the supplementation group (p = 0.028), in contrast to 3.3{\%} in the placebo group (p = 0.898). Conclusions: Antioxidant supplementation significantly reduced subfoveal fluid height. The impacts of antioxidant supplementation on BCVA remain to be elucidated in future studies.",
author = "Ari Shinojima and Miki Sawa and Tetsuju Sekiryu and Yuji Oshima and Ryusaburo Mori and Chikako Hara and Yukinori Sugano and Aki Kato and Hitomi Asato and Mitsuko Yuzawa and Fumi Gomi and Yuichiro Ogura and Tatsuro Ishibashi and Tomoaki Nanri and Tsutomu Yasukawa",
year = "2017",
month = "4",
day = "1",
doi = "10.1159/000455807",
language = "English",
volume = "237",
pages = "159--166",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy

AU - Shinojima, Ari

AU - Sawa, Miki

AU - Sekiryu, Tetsuju

AU - Oshima, Yuji

AU - Mori, Ryusaburo

AU - Hara, Chikako

AU - Sugano, Yukinori

AU - Kato, Aki

AU - Asato, Hitomi

AU - Yuzawa, Mitsuko

AU - Gomi, Fumi

AU - Ogura, Yuichiro

AU - Ishibashi, Tatsuro

AU - Nanri, Tomoaki

AU - Yasukawa, Tsutomu

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose: To investigate functional and morphological changes in patients with chronic central serous chorioretinopathy after supplementation with antioxidants containing lutein or a placebo. Procedures: One hundred eyes of 100 patients were randomly divided into 2 groups, one taking tablets with lutein plus other antioxidants and the other taking a placebo for 6 months. Best-corrected visual acuity (BCVA) and the subfoveal fluid height on optical coherence tomography were measured. Results: Seventy-nine patients (37 in the supplementation and 42 in the placebo group) completed the 6-month follow-up. In the supplementation group, mean BCVA showed significant improvement (p = 0.003), while there was no significant change in the placebo group (p = 0.589). The mean subfoveal fluid height was significantly reduced, by 28.6%, in the supplementation group (p = 0.028), in contrast to 3.3% in the placebo group (p = 0.898). Conclusions: Antioxidant supplementation significantly reduced subfoveal fluid height. The impacts of antioxidant supplementation on BCVA remain to be elucidated in future studies.

AB - Purpose: To investigate functional and morphological changes in patients with chronic central serous chorioretinopathy after supplementation with antioxidants containing lutein or a placebo. Procedures: One hundred eyes of 100 patients were randomly divided into 2 groups, one taking tablets with lutein plus other antioxidants and the other taking a placebo for 6 months. Best-corrected visual acuity (BCVA) and the subfoveal fluid height on optical coherence tomography were measured. Results: Seventy-nine patients (37 in the supplementation and 42 in the placebo group) completed the 6-month follow-up. In the supplementation group, mean BCVA showed significant improvement (p = 0.003), while there was no significant change in the placebo group (p = 0.589). The mean subfoveal fluid height was significantly reduced, by 28.6%, in the supplementation group (p = 0.028), in contrast to 3.3% in the placebo group (p = 0.898). Conclusions: Antioxidant supplementation significantly reduced subfoveal fluid height. The impacts of antioxidant supplementation on BCVA remain to be elucidated in future studies.

UR - http://www.scopus.com/inward/record.url?scp=85011837380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011837380&partnerID=8YFLogxK

U2 - 10.1159/000455807

DO - 10.1159/000455807

M3 - Article

C2 - 28171877

AN - SCOPUS:85011837380

VL - 237

SP - 159

EP - 166

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 3

ER -